1.Expression of p16 in cholangiocarcinoma-related diseases
Chinese Journal of Hepatobiliary Surgery 2010;16(11):895-896
The mutations and deletions of the MTS1/p16 gene are widespread in a variety of human tumor tissues.It has been shown that p16 plays an important role in the formation and development of cholangiocarcinoma as research on cholangiocarcinoma has progressed over the years, and it is thought that the abnormal expression of p16 in highly involved in cholangiocarcinoma-related diseases.All these findings indicate that p16 is closely related to cholangiocarcinoma.Early diagnosis of cholangiocarcinoma is still poor, so p16 may be a qualitative and quantitative tumor marker of high diagnostic value and may provide an opportunity for some new therapeutic methods such as targeted therapy.It can achieve the purpose of early diagnosis and early treatment to enhance the survival rate of patients.
2.Clinical performance evaluation on dry chemistry method of Vitros 350 for the determination of serum bilirubin
Lin YU ; Feifeng LI ; Yueting GAO ; Yongping LIN ; Tingting FAN ; Zhongmin LIU
International Journal of Laboratory Medicine 2015;(19):2812-2813,2816
Objective To evaluate clinical performance on dry chemistry method of Vitros 350 for the determination of serum bilirubin in order to ensure the quality of examination.Methods Evaluation protocols were employed to evaluate the precision,the trueness and the linearity of total bilirubin(TBIL),unconjugated bilirubin (Bu)and conjugated bilirubin (Bc)by dry chemistry method,to verify the reference ranges of TBIL,Bu and Bc simultaneously.Results The precision and trueness of TBIL,Bu and Bc were within the allowable ranges of Clinical and Laboratory Ltandards Institute (CLSI).The linear range of TBIL,Bu and Bc in our laboratory were 6.57-428.83 μmol/L,4.5-320.1 μmol/L and 4.5-364.9 μmol/L respectively.Conclusion Both technical per-formance evaluation and diagnostic performance verification of bilirubin by dry chemical detection system could meet the needs of the clinic.